Cargando…
A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment
Drug repositioning is a promising and powerful innovative strategy in the field of drug discovery. In this study, we screened a compound-library containing 800 Food and Drug Administration approved drugs for their anti-leukemic effect. All screening activities made use of human peripheral blood mono...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195271/ https://www.ncbi.nlm.nih.gov/pubmed/34123769 http://dx.doi.org/10.3389/fonc.2021.579488 |
_version_ | 1783706471682277376 |
---|---|
author | Nehdi, Atef Samman, Nosaibah Mashhour, Abdullah Alhallaj, Alshaimaa Trivilegio, Thadeo Gul, Sheraz Reinshagen, Jeanette Alaskar, Ahmed Gmati, Gamal Abuelgasim, Khadega A. Mansour, Fatmah Boudjelal, Mohamed |
author_facet | Nehdi, Atef Samman, Nosaibah Mashhour, Abdullah Alhallaj, Alshaimaa Trivilegio, Thadeo Gul, Sheraz Reinshagen, Jeanette Alaskar, Ahmed Gmati, Gamal Abuelgasim, Khadega A. Mansour, Fatmah Boudjelal, Mohamed |
author_sort | Nehdi, Atef |
collection | PubMed |
description | Drug repositioning is a promising and powerful innovative strategy in the field of drug discovery. In this study, we screened a compound-library containing 800 Food and Drug Administration approved drugs for their anti-leukemic effect. All screening activities made use of human peripheral blood mononuclear cells (PBMCs), isolated from healthy or leukemic donors. Compounds with confirmed cytotoxicity were selected and classified in three groups: i) anti-neoplastic compounds which are drugs used in leukemia treatment, ii) compounds known to have an anti-cancer effect and iii) compounds demonstrating an anti-leukemic potential for the first time. The latter group was the most interesting from a drug repositioning perspective and yielded a single compound, namely Isoprenaline which is a non-selective β-adrenergic agonist. Analysis of the cytotoxic effect of this drug indicated that it induces sustainable intracellular ATP depletion leading, over time, to necrotic cell death. We exploited the Isoprenaline-induced intracellular ATP depletion to sensitize primary leukemic cells to fludarabine (purine analogue) and Ibrutinib (Bruton’s tyrosine kinase inhibitor) treatment. In-vitro treatment of primary leukemic cells with a combination of Isoprenaline/fludarabine or Isoprenaline/Ibrutinib showed a very high synergistic effect. These combinations could constitute a new efficient regimen for CLL treatment following successful evaluation in animal models and clinical trials. |
format | Online Article Text |
id | pubmed-8195271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81952712021-06-12 A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment Nehdi, Atef Samman, Nosaibah Mashhour, Abdullah Alhallaj, Alshaimaa Trivilegio, Thadeo Gul, Sheraz Reinshagen, Jeanette Alaskar, Ahmed Gmati, Gamal Abuelgasim, Khadega A. Mansour, Fatmah Boudjelal, Mohamed Front Oncol Oncology Drug repositioning is a promising and powerful innovative strategy in the field of drug discovery. In this study, we screened a compound-library containing 800 Food and Drug Administration approved drugs for their anti-leukemic effect. All screening activities made use of human peripheral blood mononuclear cells (PBMCs), isolated from healthy or leukemic donors. Compounds with confirmed cytotoxicity were selected and classified in three groups: i) anti-neoplastic compounds which are drugs used in leukemia treatment, ii) compounds known to have an anti-cancer effect and iii) compounds demonstrating an anti-leukemic potential for the first time. The latter group was the most interesting from a drug repositioning perspective and yielded a single compound, namely Isoprenaline which is a non-selective β-adrenergic agonist. Analysis of the cytotoxic effect of this drug indicated that it induces sustainable intracellular ATP depletion leading, over time, to necrotic cell death. We exploited the Isoprenaline-induced intracellular ATP depletion to sensitize primary leukemic cells to fludarabine (purine analogue) and Ibrutinib (Bruton’s tyrosine kinase inhibitor) treatment. In-vitro treatment of primary leukemic cells with a combination of Isoprenaline/fludarabine or Isoprenaline/Ibrutinib showed a very high synergistic effect. These combinations could constitute a new efficient regimen for CLL treatment following successful evaluation in animal models and clinical trials. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8195271/ /pubmed/34123769 http://dx.doi.org/10.3389/fonc.2021.579488 Text en Copyright © 2021 Nehdi, Samman, Mashhour, Alhallaj, Trivilegio, Gul, Reinshagen, Alaskar, Gmati, Abuelgasim, Mansour and Boudjelal https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Nehdi, Atef Samman, Nosaibah Mashhour, Abdullah Alhallaj, Alshaimaa Trivilegio, Thadeo Gul, Sheraz Reinshagen, Jeanette Alaskar, Ahmed Gmati, Gamal Abuelgasim, Khadega A. Mansour, Fatmah Boudjelal, Mohamed A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment |
title | A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment |
title_full | A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment |
title_fullStr | A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment |
title_full_unstemmed | A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment |
title_short | A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment |
title_sort | drug repositioning approach identifies a combination of compounds as a potential regimen for chronic lymphocytic leukemia treatment |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195271/ https://www.ncbi.nlm.nih.gov/pubmed/34123769 http://dx.doi.org/10.3389/fonc.2021.579488 |
work_keys_str_mv | AT nehdiatef adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT sammannosaibah adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT mashhourabdullah adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT alhallajalshaimaa adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT trivilegiothadeo adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT gulsheraz adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT reinshagenjeanette adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT alaskarahmed adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT gmatigamal adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT abuelgasimkhadegaa adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT mansourfatmah adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT boudjelalmohamed adrugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT nehdiatef drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT sammannosaibah drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT mashhourabdullah drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT alhallajalshaimaa drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT trivilegiothadeo drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT gulsheraz drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT reinshagenjeanette drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT alaskarahmed drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT gmatigamal drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT abuelgasimkhadegaa drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT mansourfatmah drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment AT boudjelalmohamed drugrepositioningapproachidentifiesacombinationofcompoundsasapotentialregimenforchroniclymphocyticleukemiatreatment |